

Contains Nonbinding Recommendations

Draft Guidance on Albendazole

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Albendazole

Form/Route: Tablet/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-way crossover in-vivo
Strength: 200 mg x 2 tablets (400 mg dose)
Subjects: Healthy males and nonpregnant females, general population.
Additional Comments:

2. Type of study: Fed
Design: Single-dose, two-way crossover in-vivo
Strength: 200 mg x 2 tablets (400 mg dose)
Subjects: Healthy males and nonpregnant females, general population.
Additional Comments: Please refer to Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analytes to measure (in appropriate biological fluid): Albendazole and its active metabolite, albendazole sulfoxide, in plasma

Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Bioequivalence based on (90% CI): Albendazole

However, if you can demonstrate that it is not possible to measure albendazole in plasma accurately and reliably, please analyze the albendazole sulfoxide using the confidence interval approach.

Waiver request of in-vivo testing: Not applicable

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.